drugset
drugset / Trial / NCT02650648

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

NCT02650648 ↗

Phase 1 Completed 85 enrolled Memorial Sloan Kettering Cancer Center Y-mAbs Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for neuroblastoma. NK cells are a type of white blood cell. Funding Source- FDA OOPD

Timeline

Start
2016-01-05
Primary completion
2025-07-28
Completion
2025-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject NK cells Cell therapy 9.9e+06 cells/kg Intravenous
Subject NK cells Cell therapy 1.49e+07 cells/kg Intravenous
Subject Naxitamab Monoclonal antibody 1.68 mg/kg —
Background Cyclophosphamide Other / unclassified 50 mg/kg Intravenous
Background Cyclophosphamide Other / unclassified 1500 mg/m2 Intravenous
Background rIL-2 Unknown 600000 iu Subcutaneous

Indications

neuroblastoma